Bristol Myers Squibb and Pfizer announced a new program to sell their blockbuster blood thinner, Eliquis, directly to cash-paying patients at a discounted rate. This initiative aims to bypass traditional middlemen, including pharmacy benefit managers and insurers.
The program will reduce the monthly cost of Eliquis from a list price of approximately $606 to $346. This move is seen as a response to increasing pressure from the Trump administration to lower drug prices and to expand access for uninsured, underinsured, and self-pay patients.
Starting September 8, patients will be able to purchase the medicine directly from the Eliquis 360 Support program, with prescriptions shipped to their homes. This strategy could help mitigate the impact of government drug price negotiations, such as the Medicare negotiated price of $231 per month set to take effect next year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.